ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

9:00AM-10:30AM: Abstract Number: 0931

Rituximab versus Leflunomide in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis Despite Methotrexate Treatment- an Open Label Randomized Controlled Trial

RA – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 0762

Rituximab-treated Rheumatic Patients: B-cell Levels Predict Sero-conversion After COVID-19 Boost or Re-vaccination in Initial Vaccine Non-responders

Immunological Complications of Medical Therapy Poster

9:00AM-10:30AM: Abstract Number: 0588

S-nitrosoglutathione Reductase (GSNOR) Regulates Osteoclast Differentiation

Cytokines and Cell Trafficking Poster

9:00AM-10:30AM: Abstract Number: 0985

S100 Serum Protein Expression Is a Useful Indicator of HCQ Treatment Efficacy in SLE

SLE – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 0757

Safety and Effectiveness of Immune Checkpoint Inhibitors Combination versus Single Agent Therapy in Patients with Pre-existing Autoimmune Diseases

Immunological Complications of Medical Therapy Poster

9:00AM-10:30AM: Abstract Number: 1074

Safety and Efficacy of Dupilumab in Patients with Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis

Vasculitis – ANCA-Associated Poster II: Treatment Efficacy, Clinical Outcomes, Biomarkers

9:00AM-10:30AM: Abstract Number: 0715

Safety and Immunogenicity of Mixed COVID19 Vaccine Regimens in Immune-mediated Inflammatory Diseases: An Observational Cohort

Epidemiology and Public Health Poster I

9:00AM-10:30AM: Abstract Number: 1061

Safety and Tolerability of Aminaphtone in Systemic Sclerosis Patients: A Four-year Follow-up

Systemic Sclerosis and Related Disorders – Clinical Poster I

9:00AM-10:30AM: Abstract Number: 1077

Safety of Avacopan in ANCA-Associated Vasculitis: Combined Data from Three Clinical Trials

Vasculitis – ANCA-Associated Poster II: Treatment Efficacy, Clinical Outcomes, Biomarkers

9:00AM-10:30AM: Abstract Number: 1085

Safety of Plasmapheresis as an Adjuvant Therapy in Severe Pediatric Anti-neutrophil Cytoplasmic Antibody Associated Vasculitis: A Single Center Cohort

Vasculitis – ANCA-Associated Poster II: Treatment Efficacy, Clinical Outcomes, Biomarkers

9:00AM-10:30AM: Abstract Number: 0988

Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Enpatoran Doses in a Phase I Study of Healthy Japanese and Caucasian Participants: Feasibility of Including Asian Participants in a Phase II Study of Enpatoran

SLE – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 0796

SARS-CoV-2 Vaccine in Axial Spondyloarthritis and Psoriatic Arthritis: Does Sulfasalazine Counterbalance TNFI Impaired Immunogenicity?

Infection-related Rheumatic Disease Poster

9:00AM-10:30AM: Abstract Number: 0993

SARS-CoV-2 Vaccine Side Effects and Infections in SLE

SLE – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 1046

Scleroderma Heart Disease

Systemic Sclerosis and Related Disorders – Clinical Poster I

9:00AM-10:30AM: Abstract Number: 0665

Screening for Neurocognitive Demands in Childhood-onset Systemic Lupus Erythematosus Patients Using Pediatric Automated Neuropsychological Assessment Metrics and Association with Magnetic Resonance Imaging

SLE – Etiology and Pathogenesis Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].